GFAP and Alzheimer disease: Taken together, these findings raise the possibility that plasma Aβ42/40 and p‐τ181 may be specific markers for the development of AD, while plasma GFAP and NfL may be potential biomarkers for the development of not only AD but also other types of dementia as well.